WINTON GROUP Ltd Has $1.09 Million Stake in Vericel Corporation $VCEL

WINTON GROUP Ltd grew its stake in shares of Vericel Corporation (NASDAQ:VCEL) by 104.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 34,766 shares of the biotechnology company’s stock after buying an additional 17,730 shares during the period. WINTON GROUP Ltd owned approximately 0.07% of Vericel worth $1,094,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Huntington National Bank raised its position in shares of Vericel by 51.3% in the 3rd quarter. Huntington National Bank now owns 805 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 273 shares during the period. Abich Financial Wealth Management LLC bought a new stake in Vericel in the third quarter valued at approximately $31,000. AlphaQuest LLC increased its stake in Vericel by 135.6% in the third quarter. AlphaQuest LLC now owns 3,332 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 1,918 shares in the last quarter. Osaic Holdings Inc. raised its holdings in Vericel by 13.7% in the second quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company’s stock worth $125,000 after purchasing an additional 353 shares during the period. Finally, Smartleaf Asset Management LLC boosted its position in shares of Vericel by 178.4% during the second quarter. Smartleaf Asset Management LLC now owns 3,241 shares of the biotechnology company’s stock worth $135,000 after purchasing an additional 2,077 shares in the last quarter.

Vericel Stock Down 1.6%

NASDAQ:VCEL opened at $32.88 on Thursday. Vericel Corporation has a twelve month low of $29.24 and a twelve month high of $48.74. The business has a 50 day moving average price of $36.61 and a two-hundred day moving average price of $36.01. The company has a market cap of $1.67 billion, a P/E ratio of 106.06 and a beta of 1.22.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Thursday, February 26th. The biotechnology company reported $0.45 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.45. The company had revenue of $92.92 million for the quarter, compared to the consensus estimate of $92.66 million. Vericel had a net margin of 5.98% and a return on equity of 5.17%. The firm’s revenue was up 23.3% compared to the same quarter last year. During the same period last year, the company earned $0.38 earnings per share. As a group, analysts anticipate that Vericel Corporation will post 0.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on VCEL. Zacks Research lowered shares of Vericel from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 12th. Wall Street Zen downgraded Vericel from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Truist Financial decreased their target price on Vericel from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Thursday, December 18th. Weiss Ratings restated a “hold (c-)” rating on shares of Vericel in a report on Monday, December 29th. Finally, HC Wainwright raised their price target on Vericel from $60.00 to $64.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Five analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $56.00.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.